Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 2, pp 331–338

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer

  • Hiroyuki Yamaguchi
  • Hiroshi Soda
  • Yoichi Nakamura
  • Mineyo Takasu
  • Nanae Tomonaga
  • Hirofumi Nakano
  • Seiji Doi
  • Katsumi Nakatomi
  • Seiji Nagashima
  • Hiroshi Takatani
  • Minoru Fukuda
  • Tomayoshi Hayashi
  • Kazuhiro Tsukamoto
  • Shigeru Kohno
Original Article

DOI: 10.1007/s00280-010-1325-x

Cite this article as:
Yamaguchi, H., Soda, H., Nakamura, Y. et al. Cancer Chemother Pharmacol (2011) 67: 331. doi:10.1007/s00280-010-1325-x

Abstract

Purpose

Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment.

Methods

We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status ≤3, age ≤80 years, and stage IIIB–IV disease. In addition, EGFR mutations were analyzed in 24 patients.

Results

Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS.

Conclusions

The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib.

Keywords

Non-small cell lung cancerGefitinibSP-ASP-D

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Hiroyuki Yamaguchi
    • 1
  • Hiroshi Soda
    • 2
  • Yoichi Nakamura
    • 1
  • Mineyo Takasu
    • 3
  • Nanae Tomonaga
    • 1
  • Hirofumi Nakano
    • 1
  • Seiji Doi
    • 1
  • Katsumi Nakatomi
    • 1
  • Seiji Nagashima
    • 4
  • Hiroshi Takatani
    • 4
  • Minoru Fukuda
    • 5
  • Tomayoshi Hayashi
    • 6
  • Kazuhiro Tsukamoto
    • 3
  • Shigeru Kohno
    • 1
  1. 1.Second Department of Internal MedicineNagasaki University School of MedicineNagasakiJapan
  2. 2.Sasebo General HospitalSaseboJapan
  3. 3.Department of PharmacotherapeuticsNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  4. 4.Japanese Red-Cross Nagasaki Atomic Bomb HospitalNagasakiJapan
  5. 5.Nagasaki Municipal HospitalNagasakiJapan
  6. 6.Department of PathologyNagasaki University HospitalNagasakiJapan